EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis

Min Luo, Wenyu Li, Xuehong Wang, Yuqian Zhou iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0332345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Min Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department of the Second Xiangya Hospital, The Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Colitis, Ischemic, Cathartics. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ischemic colitis (IC) is a serious but underrecognized complication potentially associated with bowel preparation. While previous studies have reported sporadic cases, the true frequency and drug-specific associations remain unclear. This study evaluates the association between oral bowel cleansers and IC using real-world pharmacovigilance data.

Methods

We conducted a disproportionality analysis using 20 years of data (2004–2024) from the FDA Adverse Event Reporting System (FAERS). IC cases linked to bisacodyl, polyethylene glycol (PEG), and oral sulfate solution (OSS) were identified. Multivariate logistic regression was applied to explore factors associated with IC and serious clinical outcomes.

Results

Among 43,958 adverse event reports related to bowel cleansers, 75 cases of IC were identified. Bisacodyl showed the strongest disproportionality signal for IC (reporting odds ratio (ROR) = 237.25), with a reporting proportion of 7.9%, followed by PEG (ROR = 2.18) and OSS (ROR = 3.64). Older age (≥70 years) and cardiovascular comorbidities were associated with more severe outcomes, such as hospitalization and death. Notably, reports of IC associated with PEG included six fatal and three life-threatening events.

Conclusions

To our knowledge, this is one of the largest pharmacovigilance analyses exploring ischemic colitis associated with bowel preparation agents. The findings raise concerns about the presumed safety of PEG and reveal a strong disproportionality signal for bisacodyl. These results highlight the need for individualized bowel preparation strategies, especially in elderly patients with comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, IschemicCatharticsHumansMaleFemaleMiddle AgedAgedAdultPolyethylene GlycolsBisacodylAdministration, OralSulfatesPharmacovigilanceAdverse Drug Reaction Reporting SystemsAged, 80 and overAdolescentRisk FactorsUnited StatesYoung Adult

Substanzen

Polyethylene GlycolsCatharticsBisacodylSulfates

Autor:innen und Institutionen

  • Gastroenterology Department of the Second Xiangya Hospital, The Central South University, Changsha, Hunan, China.

ORCID-Profile: Yuqian Zhou

Zitieren

APA

Luo, M., Li, W., Wang, X., & Zhou, Y. (2025). Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis. PLOS One. https://doi.org/10.1371/journal.pone.0332345

Vancouver

Luo M, Li W, Wang X, Zhou Y. Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis. PLOS One. 2025. doi:10.1371/journal.pone.0332345

BibTeX
@article{Luo2025,
  author = {Luo, Min and Li, Wenyu and Wang, Xuehong and Zhou, Yuqian},
  title = {Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0332345}
}
Kostenlos starten →